APA
Caplin M. E., Pavel M., Ćwikła J. B., Phan A. T., Raderer M., Sedláčková E., Cadiot G., Wolin E. M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Gomez-Panzani E. & Ruszniewski P. (20161024). Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. : Endocrine-related cancer.
Chicago
Caplin Martyn E, Pavel Marianne, Ćwikła Jarosław B, Phan Alexandria T, Raderer Markus, Sedláčková Eva, Cadiot Guillaume, Wolin Edward M, Capdevila Jaume, Wall Lucy, Rindi Guido, Langley Alison, Martinez Séverine, Gomez-Panzani Edda and Ruszniewski Philippe. 20161024. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. : Endocrine-related cancer.
Harvard
Caplin M. E., Pavel M., Ćwikła J. B., Phan A. T., Raderer M., Sedláčková E., Cadiot G., Wolin E. M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Gomez-Panzani E. and Ruszniewski P. (20161024). Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. : Endocrine-related cancer.
MLA
Caplin Martyn E, Pavel Marianne, Ćwikła Jarosław B, Phan Alexandria T, Raderer Markus, Sedláčková Eva, Cadiot Guillaume, Wolin Edward M, Capdevila Jaume, Wall Lucy, Rindi Guido, Langley Alison, Martinez Séverine, Gomez-Panzani Edda and Ruszniewski Philippe. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. : Endocrine-related cancer. 20161024.